热门资讯> 正文
Lixte Biotechnology任命Jan Schellens为CMO
2024-06-03 22:21
- Lixte Biotechnology Holdings Inc Warrants (01/01/2025)(LIXTW) 0
- Lixte Biotechnology Holdings(LIXT) 0
- LIXTE Biotechnology Holdings(NASDAQ:LIXT) has announced the appointment of Jan Schellens, M.D., Ph.D., as CMO.
- He assumes the CMO role at LIXTE effective Aug. 1, 2024, succeeding James S. Miser, M.D., who is leaving the Co. after serving in this capacity since 2020.
- "He brings a highly relevant background to LIXTE, and we are fortunate in attracting him to our organization, as we continue to make progress with LB-100 to enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer." said Bas van der Baan, LIXTE’s CEO.
More on Lixte Biotechnology Holdings, Inc.
- Lixte stock soars on preclinical data for lead drug LB-100
- Financial information for Lixte Biotechnology Holdings, Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
